Page 3 - துறவி லூயிஸ் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cybin” or the “ Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the formation of its Clinical Advisory Board, with the additions of Maurizio Fava, MD, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital; Lynn Marie Morski, MD, Esq., President of the Psychedelic Medicine Association; and Anthony Back, MD, Professor in the Department of Medicine and Division of Oncology at the University of Washington. The Clinical Advisory Board will be chaired by Alex Belser, PhD, Cybin’s Chief Clinical Officer. “We are delighted to welcome three accomplished experts in their respective fields to guide the strategic development of Cybin’s clinical programs. Together, Drs. Fava, Morski, and Back add unparalleled clinical expertise and strengthen our position to advance psychedelic therapeutics. Their insights will be especially valuable as we move our development pipeline through clinical trials,” s

United statesUnited kingdomAlex belserDoug drysdaleLynn marie morskiDivision of clinical researchCybin incThomas jefferson school of lawPsychiatry clinical trials networkDean for clinical translational researchUniversity of washingtonGeorgetown universitySaint louis university school of medicineLife instituteYork universityDivision of oncology